KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ginkgo Bioworks Holdings (DNA) Operating Expenses (2020 - 2025)

Ginkgo Bioworks Holdings (DNA) has disclosed Operating Expenses for 4 consecutive years, with $212.9 million as the latest value for Q4 2023.

  • For the quarter ending Q4 2023, Operating Expenses fell 35.33% year-over-year to $212.9 million, compared with a TTM value of $1.1 billion through Dec 2023, down 58.44%, and an annual FY2025 reading of $485.4 million, down 38.3% over the prior year.
  • Operating Expenses was $212.9 million for Q4 2023 at Ginkgo Bioworks Holdings, down from $341.8 million in the prior quarter.
  • Across five years, Operating Expenses topped out at $1.8 billion in Q4 2021 and bottomed at $45.9 million in Q3 2020.
  • Average Operating Expenses over 4 years is $434.1 million, with a median of $280.6 million recorded in 2023.
  • The sharpest move saw Operating Expenses skyrocketed 1984.49% in 2021, then crashed 82.05% in 2022.
  • Year by year, Operating Expenses stood at $87.9 million in 2020, then surged by 1984.49% to $1.8 billion in 2021, then plummeted by 82.05% to $329.1 million in 2022, then plummeted by 35.33% to $212.9 million in 2023.
  • Business Quant data shows Operating Expenses for DNA at $212.9 million in Q4 2023, $341.8 million in Q3 2023, and $264.7 million in Q2 2023.